HUP0203403A2 - Új imidazol-száemazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Új imidazol-száemazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0203403A2 HUP0203403A2 HU0203403A HUP0203403A HUP0203403A2 HU P0203403 A2 HUP0203403 A2 HU P0203403A2 HU 0203403 A HU0203403 A HU 0203403A HU P0203403 A HUP0203403 A HU P0203403A HU P0203403 A2 HUP0203403 A2 HU P0203403A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- optionally substituted
- aryl
- heterocyclyl
- arylalkyl
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- -1 -X-R4 group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 102000012753 TIE-2 Receptor Human genes 0.000 abstract 1
- 108010090091 TIE-2 Receptor Proteins 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
Abstract
A találmány nem megfelelő, túlzott vagy nem kívánatos angiogenezisés/vagy túlzott Tie2 receptor aktivitás kezelésére felhasználható (I)általános képletű vegyületekre - amelyek képletében V metincsoportvagy nitrogénatom; Ar adott esetben szubsztituált 2-naftil-, 1-naftil-vagy triciklusos heteroaromás csoport; Y -NR10R11, -NR10C(Z)NR10R11, -NR10C(Z)NR10C(Z)-OR11, -NR10COOR11 vagy -NR10SO2R11 csoport; n értéke0, 1, 2, 3 vagy 4; X oxigénatom, metiléncsoport, kénatom vagyiminocsoport; Z oxigén- vagy kénatom; R1 hidrogénatom, -X-R4 csoport,halogénatom, hidroxi-, adott esetben szubsztituált alkil-, alkil-szulfinil-, -CH2OR5, amino-, mono- vagy dialkil-amino-, -N(R6)C(O)R7,-N(R6)-S(O)2R8 csoport vagy egy N-heterociklil-csoport, amely adottesetben egy, az oxigén-, kénatom vagy -NR9 csoport közül kiválasztotttovábbi heteroatomot tartalmazhat; R2 és R3 adott esetbenszubsztituált alkilcsoport, vagy R2 és R3 egymáshoz kapcsolódva egyadott esetben szubsztituált cikloalkil- vagy cikloalkenilcsoportotképez, vagy R2 és R3 a szénatommal együtt egy adott esetbenszubsztituált heterociklilcsoportot képez; R4 adott esetbenszubsztituált alkil-, aril-, aril-alkil-, heterociklil-, heterociklil-alkil-, heteroaril- vagy heteroaril-alkil-csoport; R5 hidrogénatom, -C(Z)R12 csoport vagy adott esetben szubsztituált alkil-, aril-, aril-alkil- vagy -S(O)2R8 csoport; R6 hidrogénatom vagy alkilcsoport; R7hidrogénatom, alkil-, cikloalkil-, aril-, aril-alkil-, heteroaril-,heteroaril-alkil-, heterociklil- vagy heterociklil-alkil-csoport; R8alkil-, cikloalkil-, aril-, aril-alkil-, heteroaril-, heteroaril-alkil-, heterociklil- vagy heterociklil-alkil-csoport; R9hidrogénatom, alkil-, cikloalkil- vagy arilcsoport; R10 és R12hidrogénatom vagy adott esetbén szubsztituált alkil-, cikloalkil-,cikloalkil-alkil-, aril-, aril-alkil-, heterociklil-, heterociklil-alkil-, heteroaril- vagy heteroaril-alkil-csoport; és R11 hidrogénatomvagy adott esetben szubsztituált alkil-, cikloalkil-, cikloalkil-alkil-, aril-, aril-alkil-, heterociklil-, heterociklil-alkil-,heteroaril- vagy heteroaril-alkil)-csoport; vagy R10 és R11 anitrogénatommal együtt egy adott esetben további heteroatomottartalmazó gyűrűs csoportot képez, és gyógyászatilag elfogadhatósóikra vonatkozik. A találmány kiterjed a vegyületeket tartalmazógyógyszerkészítményekre és alkalmazásukra. Ó
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16688599P | 1999-11-22 | 1999-11-22 | |
| US16689599P | 1999-11-22 | 1999-11-22 | |
| US16681499P | 1999-11-22 | 1999-11-22 | |
| US16688699P | 1999-11-22 | 1999-11-22 | |
| PCT/US2000/031791 WO2001037835A1 (en) | 1999-11-22 | 2000-11-20 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0203403A2 true HUP0203403A2 (hu) | 2003-02-28 |
| HUP0203403A3 HUP0203403A3 (en) | 2004-01-28 |
Family
ID=27496721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203403A HUP0203403A3 (en) | 1999-11-22 | 2000-11-20 | New imidazole derivatives, pharmaceutical compositions containing them and their use |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US7189745B1 (hu) |
| EP (2) | EP1232153B1 (hu) |
| JP (2) | JP2003514906A (hu) |
| KR (1) | KR20020050294A (hu) |
| CN (1) | CN1543346A (hu) |
| AT (2) | ATE382044T1 (hu) |
| AU (2) | AU1623601A (hu) |
| BR (1) | BR0015532A (hu) |
| CA (1) | CA2395564A1 (hu) |
| CZ (1) | CZ20021746A3 (hu) |
| DE (2) | DE60015594T2 (hu) |
| ES (2) | ES2228629T3 (hu) |
| HK (1) | HK1050190A1 (hu) |
| HU (1) | HUP0203403A3 (hu) |
| IL (2) | IL149150A0 (hu) |
| MX (1) | MXPA02005106A (hu) |
| NO (1) | NO20022318D0 (hu) |
| NZ (1) | NZ518032A (hu) |
| PL (1) | PL355912A1 (hu) |
| TR (1) | TR200201364T2 (hu) |
| WO (2) | WO2001037835A1 (hu) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| MXPA02005106A (es) | 1999-11-22 | 2002-11-07 | Smithkline Beecham Plc | Compuestos novedosos. |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| JP4217480B2 (ja) * | 2000-11-20 | 2009-02-04 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| GB0121488D0 (en) * | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| EP1423383B1 (en) | 2001-09-05 | 2008-08-06 | Smithkline Beecham Plc | Pyridine substituted furan derivatives as raf kinase inhibitors |
| EP1432699A1 (en) * | 2001-09-05 | 2004-06-30 | Smithkline Beecham Plc | Pyridylfurans and pyrroles as raf kinase inhibitors |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| WO2003076434A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
| EP1537112B1 (en) | 2002-08-06 | 2006-04-19 | Astrazeneca AB | Condensed pyridines and pyrimidines with tie2 (tek) activity |
| EP1539121A4 (en) | 2002-08-29 | 2008-08-13 | Scios Inc | METHOD OF REQUESTING OSTEOGENESIS |
| EP2426122A1 (en) * | 2002-10-24 | 2012-03-07 | Merck Patent GmbH | Methylene urea derivative as RAF kinasse inhibitors |
| BR0315580A (pt) * | 2002-10-24 | 2005-08-30 | Merck Patent Gmbh | Derivados de metileno uréia |
| GB0230089D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| US7361669B2 (en) | 2003-01-02 | 2008-04-22 | Millennium Pharmaceuticals, Inc. | Compositions and method for inhibiting TGF-β |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
| US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
| BRPI0414869A (pt) * | 2003-10-02 | 2006-11-28 | Irm Llc | compostos e composições como inibidores da proteìna quinase |
| US7250434B2 (en) | 2003-12-22 | 2007-07-31 | Janssen Pharmaceutica N.V. | CCK-1 receptor modulators |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| WO2005082853A1 (en) * | 2004-02-26 | 2005-09-09 | Merck Patent Gmbh | Semicarbazide derivatives as kinase inhibitors |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| WO2007016286A1 (en) * | 2005-07-28 | 2007-02-08 | Janssen Pharmaceutica N.V. | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine |
| EP1934213A1 (en) | 2005-09-30 | 2008-06-25 | Astra Zeneca AB | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| MX2008013990A (es) | 2006-05-09 | 2009-01-29 | Pfizer Prod Inc | Derivados de cicloalquilamino acidos. |
| CA2689092C (en) | 2007-06-07 | 2013-01-15 | Amgen Inc. | Raf kinase modulators and methods of use |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| US8129394B2 (en) * | 2008-03-21 | 2012-03-06 | Novartis Ag | Heteroaryl-substituted imidazole compounds and uses thereof |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| US8835450B2 (en) * | 2009-10-08 | 2014-09-16 | Glaxosmithkline Llc | Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer |
| PL2488033T3 (pl) * | 2009-10-16 | 2019-12-31 | Novartis Ag | Kombinacja zawierająca inhibitor MEK i inhibitor B-raf |
| WO2011077387A1 (en) * | 2009-12-22 | 2011-06-30 | Csir | Inhibition of the activity of kinase and synthetase enzymes |
| CN103159735B (zh) * | 2011-12-10 | 2015-12-09 | 通化济达医药有限公司 | 取代的咪唑激酶抑制剂 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| US10605785B2 (en) * | 2017-06-07 | 2020-03-31 | General Electric Company | Sensor system and method |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
| US3940486A (en) | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
| US4447413A (en) * | 1980-05-08 | 1984-05-08 | Aviation Chemical, Inc. | Drift influencing composition |
| US4348404A (en) | 1980-07-21 | 1982-09-07 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines |
| DD201677A5 (de) | 1980-07-25 | 1983-08-03 | Ciba Geigy | Verfahren zur herstellung von trisubstituierten imidazolderivaten |
| US5166214A (en) | 1988-12-05 | 1992-11-24 | Du Pont Merck Pharmaceutical Company | Use of imidazoles for the treatment of atherosclerosis |
| US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| US5179117A (en) | 1991-12-20 | 1993-01-12 | Du Pont Merck Pharmaceutical Company | Antihypercholesterolemic 2-substituted imidazoles |
| US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| US5310748A (en) | 1992-05-11 | 1994-05-10 | The Du Pont Merck Pharmaceutical Company | Imidazoles for the treatment of atherosclerosis |
| DE69401486T2 (de) | 1993-11-12 | 1997-04-30 | Ishihara Sangyo Kaisha | Verfahren zur Herstellung 2-cyanoimidazol Derivate |
| US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| EP0833664A1 (en) | 1995-06-12 | 1998-04-08 | G.D. SEARLE & CO. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b 4? receptor antagonist for the treatment of inflammations |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| EP0889887A4 (en) | 1996-03-25 | 2003-06-11 | Smithkline Beecham Corp | TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES |
| WO1997036587A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | A method of treating cancer |
| JP3418624B2 (ja) | 1996-06-10 | 2003-06-23 | メルク エンド カンパニー インコーポレーテッド | サイトカイン阻害活性を有する置換イミダゾール類 |
| UA67732C2 (uk) | 1996-10-15 | 2004-07-15 | Г.Д. Сьорл & Ко. | Інгібітори циклооксигенази-2 для лікування і попередження неоплазії та спосіб лікування |
| JP4380803B2 (ja) | 1997-06-12 | 2009-12-09 | アベンテイス・フアルマ・リミテツド | イミダゾリル−環式アセタール |
| GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| KR20010014288A (ko) | 1997-06-30 | 2001-02-26 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 염증성 질환의 치료에 유용한 2-치환된 이미다졸 |
| WO1999021555A2 (en) | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Adenosine a3 receptor antagonists |
| UA67763C2 (uk) * | 1997-12-22 | 2004-07-15 | Байер Фармасьютікалс Корпорейшн | Арил- та гетероарилзаміщені гетероциклічні похідні сечовини, фармацевтична композиція та спосіб лікування захворювання, спричиненого кіназою raf |
| EP1049664B1 (en) | 1997-12-22 | 2005-03-16 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| KR20010025087A (ko) | 1998-05-22 | 2001-03-26 | 스튜어트 알. 수터 | 신규한 2-알킬 치환된 이미다졸 화합물 |
| AU4395399A (en) | 1998-07-02 | 2000-01-24 | Sankyo Company Limited | Five-membered heteroaryl compounds |
| US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| WO2000026209A1 (en) * | 1998-11-03 | 2000-05-11 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
| AU2039800A (en) | 1998-12-04 | 2000-06-26 | Ontogen Corporation | 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins |
| WO2000064422A2 (en) | 1999-04-27 | 2000-11-02 | Smithkline Beecham P.L.C. | Novel treatment of neurotraumatic conditions with raf inhibitor |
| MXPA02005106A (es) | 1999-11-22 | 2002-11-07 | Smithkline Beecham Plc | Compuestos novedosos. |
| WO2001066539A1 (en) | 2000-03-06 | 2001-09-13 | Smithkline Beecham P.L.C. | Imidazol derivatives as raf kinase inhibitors |
| GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
| EP1318992B1 (en) | 2000-09-21 | 2005-07-27 | Smithkline Beecham Plc | Imidazole derivatives as raf kinase inhibitors |
| JP4217480B2 (ja) | 2000-11-20 | 2009-02-04 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| EP1432699A1 (en) | 2001-09-05 | 2004-06-30 | Smithkline Beecham Plc | Pyridylfurans and pyrroles as raf kinase inhibitors |
| GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
| EP1423383B1 (en) | 2001-09-05 | 2008-08-06 | Smithkline Beecham Plc | Pyridine substituted furan derivatives as raf kinase inhibitors |
| EP1432703A1 (en) | 2001-09-05 | 2004-06-30 | Smithkline Beecham Plc | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
-
2000
- 2000-11-20 MX MXPA02005106A patent/MXPA02005106A/es unknown
- 2000-11-20 NZ NZ518032A patent/NZ518032A/en unknown
- 2000-11-20 CN CNA008159491A patent/CN1543346A/zh active Pending
- 2000-11-20 EP EP00977660A patent/EP1232153B1/en not_active Expired - Lifetime
- 2000-11-20 US US10/130,018 patent/US7189745B1/en not_active Expired - Fee Related
- 2000-11-20 IL IL14915000A patent/IL149150A0/xx active IP Right Grant
- 2000-11-20 AU AU16236/01A patent/AU1623601A/en not_active Abandoned
- 2000-11-20 CA CA002395564A patent/CA2395564A1/en not_active Abandoned
- 2000-11-20 ES ES00977660T patent/ES2228629T3/es not_active Expired - Lifetime
- 2000-11-20 JP JP2001540087A patent/JP2003514906A/ja not_active Withdrawn
- 2000-11-20 US US10/130,019 patent/US7026336B1/en not_active Expired - Fee Related
- 2000-11-20 ES ES00978816T patent/ES2298165T3/es not_active Expired - Lifetime
- 2000-11-20 EP EP00978816A patent/EP1233769B1/en not_active Expired - Lifetime
- 2000-11-20 BR BR0015532-2A patent/BR0015532A/pt not_active Application Discontinuation
- 2000-11-20 AU AU15299/01A patent/AU1529901A/en not_active Abandoned
- 2000-11-20 PL PL00355912A patent/PL355912A1/xx not_active Application Discontinuation
- 2000-11-20 JP JP2001539450A patent/JP2003514860A/ja active Pending
- 2000-11-20 DE DE60015594T patent/DE60015594T2/de not_active Expired - Fee Related
- 2000-11-20 AT AT00978816T patent/ATE382044T1/de not_active IP Right Cessation
- 2000-11-20 AT AT00977660T patent/ATE281451T1/de not_active IP Right Cessation
- 2000-11-20 HU HU0203403A patent/HUP0203403A3/hu unknown
- 2000-11-20 TR TR2002/01364T patent/TR200201364T2/xx unknown
- 2000-11-20 WO PCT/US2000/031791 patent/WO2001037835A1/en active Search and Examination
- 2000-11-20 WO PCT/GB2000/004413 patent/WO2001038324A2/en active IP Right Grant
- 2000-11-20 DE DE60037597T patent/DE60037597T2/de not_active Expired - Fee Related
- 2000-11-20 KR KR1020027006476A patent/KR20020050294A/ko not_active Application Discontinuation
- 2000-11-20 CZ CZ20021746A patent/CZ20021746A3/cs unknown
-
2002
- 2002-04-15 IL IL149150A patent/IL149150A/en not_active IP Right Cessation
- 2002-05-15 NO NO20022318A patent/NO20022318D0/no not_active Application Discontinuation
-
2003
- 2003-01-29 HK HK03100744.6A patent/HK1050190A1/zh unknown
-
2006
- 2006-09-19 US US11/533,034 patent/US20070010534A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0203403A2 (hu) | Új imidazol-száemazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0303652A2 (hu) | Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0301745A2 (hu) | Ciklopentánindolok, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása | |
| HUP0203973A2 (hu) | Szulfonamid-tartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0203971A2 (hu) | Imidazoimidazolok és -triazolok mint gyulladásellenes szerek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0301005A2 (hu) | Pirrolotriazin kináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0200310A2 (hu) | Triciklikus pirazolszármazékok alkalmazása gyógyszerkészítmények előállítására és az új vegyületek | |
| EP0638560A4 (en) | MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *. | |
| DE60140456D1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| HUP9801883A2 (hu) | Farnezil-protein transzferáz enzim gátló piperazinszármazékok, előállításuk, alkalmazásuk, és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0401900A2 (hu) | 3-Szubsztituált-4-pirimidon-származékok, ezeket tartalmazó gyógyászati készítmények és intermedierjeik | |
| HUP0204083A2 (hu) | 2-Amino-nikotin-amid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és VEGF receptor tirozin kináz inhibitorként való alkalmazásuk | |
| HUP0004845A2 (hu) | PPAR-gamma agonista aktivitással rendelkező szubsztituált 4-hidroxi-fenil-alkánsav-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| ES2196396T3 (es) | Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. | |
| HUP0302167A2 (hu) | Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
| HUP0401009A2 (hu) | 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0204245A2 (hu) | Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0202678A2 (hu) | Alkilén-diamin-csoporttal helyettesített pirazolo[1,5,-a]-1,5-pirimidin és pirazolo[1,5-a]-1,3,5-triazin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0203122A2 (hu) | Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0204474A2 (hu) | 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0500440A2 (hu) | Acil-4-karboxi-fenil-karbamid-származékok, azokat tartalmazó gyógyszerkészítmények, eljárás ezek előállítására és ezek alkalmazása | |
| HUP0104816A2 (hu) | 3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra | |
| HUP0301801A2 (hu) | Imidazo[1,2-a]pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0402376A2 (hu) | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények |